Organisation paid for research Program year 2022 Source: CMS Open Payments

Arthritis Center

Neither a doctor nor a teaching hospital

Research payments

$258,528

148 payments

Through program year 2022, Arthritis Center is reported as receiving $258,528 in research payments, across 148 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$11,441	6
2021	Research	$72,045	55
2020	Research	$152,336	83
2019	Research	$22,706	4

Breakdown

Who paid Research payments · program years 2019–2022

AbbVie, Inc. $202,262 127 payments
Novartis Pharmaceuticals Corporation $32,913 7 payments
GlaxoSmithKline, LLC. $11,912 8 payments
Ucb SA $11,441 6 payments

Studies the money was for Research payments · program years 2019–2022

M15-554 $44,933 29 payments
M15-998 $29,304 15 payments
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) $17,626 18 payments
M14-465 $17,270 9 payments
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) $16,263 14 payments
M13-538 $14,657 9 payments
M13-549 $14,528 7 payments
A Phase III Randomized Double Blind Placebo Controlled Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy at 24 Weeks and to Assess the Long Term Safety Tolerability and Efficacy Up to 3 Years in Subjects With Active PS $13,871 2 payments
A 5-Year Prospective Observational Registry to Assess Adverse Events O $11,912 8 payments
A Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) with Upadacitinib (ABT-494) $11,738 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.